GlassScriptPhysician profile
Cari Dahlman
NPI 1508153651
$2,082.88
in general payments reported to CMS, 2019-2025
14 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $640 · 2023: $456 · 2024: $535 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.95 | 2023-2025 | |
| Merz North America, INC. | $480.93 | 2022-2024 | Xeomin |
| Allergan, INC. | $282.87 | 2021-2022 | |
| Galderma Laboratories, L.P. | $156.32 | 2021-2023 | |
| Novo Nordisk INC | $135.71 | 2022 | |
| Revance Therapeutics, INC. | $102.57 | 2024-2025 | Daxxify |
| Pfizer INC. | $86.40 | 2021 | |
| Cranial Technologies, INC | $54.31 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.63 | 2021 | |
| Merck Sharp & Dohme LLC | $16.56 | 2021 | |
| Adlon Therapeutics L.P. | $16.04 | 2021 | |
| Glaxosmithkline, LLC. | $16.02 | 2021 | |
| Sanofi Pasteur INC. | $15.69 | 2021 | |
| Corium, LLC | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cari Dahlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.